Martingale Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$37.1M Sell
40,286
-183
-0.5% -$186K 0.93% 12
2025
Q4
$43.5M Buy
40,469
+3,685
+10% +$3.52M 1.11% 7
2025
Q3
$28.1M Sell
36,784
-12,612
-26% -$9.39M 0.71% 31
2025
Q2
$38.5M Buy
49,396
+355
+0.7% +$276K 0.94% 20
2025
Q1
$40.5M Buy
49,041
+1,801
+4% +$1.5M 1.03% 15
2024
Q4
$36.5M Sell
47,240
-9,490
-17% -$7.86M 0.89% 21
2024
Q3
$50.3M Sell
56,730
-12,602
-18% -$11.3M 1.15% 5
2024
Q2
$62.8M Sell
69,332
-14,329
-17% -$11.5M 1.36% 4
2024
Q1
$65.1M Sell
83,661
-5,898
-7% -$4.2M 1.3% 3
2023
Q4
$52.2M Sell
89,559
-22,549
-20% -$13.2M 1.07% 13
2023
Q3
$60.2M Sell
112,108
-33,004
-23% -$17M 1.27% 3
2023
Q2
$68.1M Sell
145,112
-35,981
-20% -$15.1M 1.33% 2
2023
Q1
$62.2M Sell
181,093
-3,761
-2% -$1.27M 1.2% 6
2022
Q4
$67.6M Sell
184,854
-21,839
-11% -$7.74M 1.32% 3
2022
Q3
$66.8M Sell
206,693
-14,717
-7% -$4.66M 1.33% 3
2022
Q2
$71.8M Sell
221,410
-46,374
-17% -$13.9M 1.31% 4
2022
Q1
$76.7M Sell
267,784
-29,155
-10% -$7.5M 1.15% 8
2021
Q4
$82M Sell
296,939
-30,416
-9% -$7.71M 1.05% 14
2021
Q3
$75.6M Sell
327,355
-92,476
-22% -$22.8M 0.99% 15
2021
Q2
$96.4M Sell
419,831
-48,581
-10% -$9.76M 1.1% 14
2021
Q1
$87.5M Sell
468,412
-55,655
-11% -$10.9M 1.01% 18
2020
Q4
$88.5M Buy
524,067
+4,901
+0.9% +$732K 1% 19
2020
Q3
$76.8M Sell
519,166
-4,501
-0.9% -$697K 0.92% 19
2020
Q2
$86M Sell
523,667
-10,885
-2% -$1.67M 1.01% 7
2020
Q1
$74.2M Buy
534,552
+15,388
+3% +$2.11M 0.98% 10
2019
Q4
$68.2M Buy
519,164
+28,110
+6% +$3.26M 0.7% 17
2019
Q3
$54.9M Buy
491,054
+32,800
+7% +$3.65M 0.56% 38
2019
Q2
$50.8M Sell
458,254
-6,316
-1% -$744K 0.53% 46
2019
Q1
$60.3M Sell
464,570
-92,603
-17% -$11.3M 0.65% 22
2018
Q4
$64.5M Sell
557,173
-70,061
-11% -$7.83M 0.85% 8
2018
Q3
$67.3M Sell
627,234
-11,454
-2% -$1.15M 0.79% 11
2018
Q2
$54.5M Buy
638,688
+8,897
+1% +$731K 0.67% 18
2018
Q1
$48.7M Buy
629,791
+70,107
+13% +$5.64M 0.63% 26
2017
Q4
$47.3M Buy
559,684
+19,614
+4% +$1.67M 0.63% 25
2017
Q3
$46.2M Buy
540,070
+207,024
+62% +$17M 0.62% 26
2017
Q2
$27.4M Buy
333,046
+196,167
+143% +$16M 0.39% 85
2017
Q1
$11.5M Sell
136,879
-216,170
-61% -$17.3M 0.17% 159
2016
Q4
$26M Sell
353,049
-99,230
-22% -$7.39M 0.37% 81
2016
Q3
$36.3M Sell
452,279
-2,599
-0.6% -$208K 0.54% 36
2016
Q2
$35.8M Buy
454,878
+80,099
+21% +$6.03M 0.59% 38
2016
Q1
$27M Buy
374,779
+37,551
+11% +$2.84M 0.53% 37
2015
Q4
$28.4M Buy
337,228
+5,301
+2% +$440K 0.63% 25
2015
Q3
$27.8M Sell
331,927
-22,506
-6% -$1.9M 0.68% 26
2015
Q2
$29.6M Buy
354,433
+22,193
+7% +$1.69M 0.69% 26
2015
Q1
$24.1M Buy
332,240
+49,389
+17% +$3.52M 0.58% 28
2014
Q4
$19.5M Buy
282,851
+21,932
+8% +$1.48M 0.54% 39
2014
Q3
$16.9M Sell
260,919
-27,715
-10% -$1.75M 0.53% 34
2014
Q2
$17.9M Buy
288,634
+12,172
+4% +$726K 0.56% 31
2014
Q1
$16.3M Buy
276,462
+5,432
+2% +$303K 0.55% 35
2013
Q4
$13.8M Buy
271,030
+23,833
+10% +$1.19M 0.48% 35
2013
Q3
$12.4M Buy
247,197
+26,191
+12% +$1.37M 0.44% 41
2013
Q2
$10.9M Buy
+221,006
New +$12M 0.4% 49

Other funds holding LLY

Martingale Asset Management's LLY Position: Q1 2026 in Review

Martingale Asset Management reduced its Eli Lilly (LLY) stake by 0.45% in Q1 2026, selling an estimated $186K and leaving 40,286 shares worth $37.1M. The position accounts for 0.93% of the portfolio, ranked #12.

Martingale Asset Management first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $96.4M in Q2 2021. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Martingale Asset Management held 40,286 shares of Eli Lilly worth $37.1M as of Q1 2026.
  • Martingale Asset Management sold 183 Eli Lilly shares in Q1 2026, an estimated $186K.
  • Eli Lilly made up 0.93% of Martingale Asset Management's portfolio in Q1 2026, its #12 holding.
  • Martingale Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Martingale Asset Management's Eli Lilly position peaked at $96.4M in Q2 2021.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.